Amber Robinson, DO
Family Medicine · Fort Worth, TXNPI 1275761082
Payments from drug & device makers
Across 129 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$763
- GSK$388
- Merck$208
- Novo Nordisk$160
- Boehringer Ingelheim$152
- Pfizer$125
- plus $1K from 35 others
What the payments were for
- Food & beverage$2,931100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 5 | $763 |
| GSK | 20 | $388 |
| Merck | 13 | $208 |
| Novo Nordisk | 11 | $160 |
| Boehringer Ingelheim | 9 | $152 |
| Pfizer | 7 | $125 |
| Lilly USA, LLC | 7 | $106 |
| Genentech USA, Inc. | 4 | $86 |
| AbbVie(2 entities) | 4 | $77 |
| Sanofi Pasteur Inc. | 4 | $72 |
| Astellas Pharma US Inc | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $47 |
| Alk-abello, Inc | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $38 |
| AstraZeneca | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| Bayer | 2 | $33 |
| Medtronic | 1 | $32 |
| Dexcom, Inc. | 2 | $31 |
| Seqirus USA Inc | 2 | $30 |
| Corium, LLC | 1 | $29 |
| Gilead | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Kaleo, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Cranial Technologies, Inc | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
| Vistapharm, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,931 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $30,514 |
| JanuviaSitagliptin Phosphate | 15 | $18,767 |
| JardianceEmpagliflozin | 18 | $15,631 |
| FarxigaDapagliflozin Propanediol | 12 | $12,599 |
| MyrbetriqMirabegron | 12 | $11,341 |
| OzempicSemaglutide | 12 | $11,047 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,521 |
| Levothyroxine Sodium | 182 | $1,714 |
| SynthroidLevothyroxine Sodium | 21 | $1,513 |
| Rosuvastatin Calcium | 101 | $1,464 |
| Atorvastatin Calcium | 142 | $1,437 |
| Metoprolol Succinate | 86 | $1,426 |
| Losartan Potassium | 106 | $1,358 |
| Lisinopril | 107 | $1,024 |
| Gabapentin | 51 | $937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $125 | $30,51435 claims |
| MerckJanuvia | $208 | $18,76715 claims |
| Boehringer IngelheimJardiance | $152 | $15,63118 claims |
| AstraZenecaFarxiga | $36 | $12,59912 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $11,34112 claims |
| Novo NordiskOzempic | $160 | $11,04712 claims |
| AbbVieSynthroid | $77 | $1,51321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.